{"nctId":"NCT01878526","briefTitle":"Gastroesophageal Reflux Treatment in Scleroderma","startDateStruct":{"date":"2013-06"},"conditions":["Gastroesophageal Reflux Disease","Systemic Sclerosis","Scleroderma"],"count":80,"armGroups":[{"label":"Omeprazole plus alginic acid and placebo of domperidone","type":"EXPERIMENTAL","interventionNames":["Drug: Alginic acid","Drug: placebo (for domperidone)"]},{"label":"Omeprazole plus domperidone and placebo of alginic acid","type":"EXPERIMENTAL","interventionNames":["Drug: Domperidone","Drug: placebo (of alginic acid)"]}],"interventions":[{"name":"Alginic acid","otherNames":["Algycon"]},{"name":"placebo (for domperidone)","otherNames":[]},{"name":"Domperidone","otherNames":["Molax"]},{"name":"placebo (of alginic acid)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Phase 1 SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 1 study for evaluation the prevalence of omeprazole resistant-GERD\n\nInclusion criteria:\n\n1. SSc patients aged between 18 and 65 years.\n2. Clinically diagnosed as GERD and GERD-questionnaire score \\>3\n3. Must not receive any proton pump inhibitor (PPI) or prokinetic drug within 2 weeks before baseline evaluation\n\nExclusion criteria:\n\n1. Pregnancy or lactation\n2. Previous history of gastroesophageal surgery or endoscopic therapy due to severe erosive esophagitis\n3. Present of Barrett's esophagus\n4. Bedridden and confined to no self-care\n5. Evidence of active malignant disease\n6. Present of uncontrolled or severe medical problems such as asthma, angina, hepatic or renal diseases\n7. Present of active infection that needs systemic antibiotic\n8. Allergic history of omeprazole\n9. Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate\n\nPhase 2 randomized parallel study SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 2 study.\n\nInclusion criteria:\n\n1. SSc patients who completed the phase 1 study.\n2. The subjects were defined as PPI-resistance.\n3. The subject must be willing to continue phase 2 study.\n\nExclusion criteria:\n\n1. Pregnancy\n2. Present of uncontrolled or severe medical problems\n3. Present of active infection\n4. Allergic history of alginic acid or domperidone\n5. Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate\n6. Chewing difficulty","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS)","description":"VAS scale 0-100 was applied for an outcome measurement of the severity of heart burn. The VAS scale 0 was no symptoms of heart burn and scale 100 was a maximum symptom of heart burn. The changing of the severity of heart burn was the changing of VAS before and after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"13.1"},{"groupId":"OG001","value":"17.2","spread":"13.9"}]}]}]},{"type":"PRIMARY","title":"Changing of the Severity of Regurgitation","description":"VAS scale 0-100 was applied for an outcome measurement of the severity of regurgitation. The VAS scale 0 was no symptoms of regurgitation and scale 100 was a maximum symptom of regurgitation. The changing of the severity of regurgitation was the changing of VAS before and after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":"15.9"},{"groupId":"OG001","value":"23.1","spread":"15.1"}]}]}]},{"type":"SECONDARY","title":"Changing of Frequency of Symptoms in SSc Related Omeprazole Resistant GERD Evaluated by Frequency Scale for the Symptoms of GERD (FSSG)","description":"Unit scale 0-48 was applied for an outcome measurement of the frequency of symptoms. The unit scale 0 was no symptom and scale 48 was usual symptom of GERD. The changing of the frequency of symptoms was the changing of the unit scale before and after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"3.3"},{"groupId":"OG001","value":"4.7","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"the Prevalence of Omeprazole-resistant GERD in SSc After 4 Weeks Treatment With Omeprazole","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Changing of the Quality of Life Which is Evaluated by EQ-5DTM","description":"VAS scale 0-100 was applied for an outcome measurement of the quality of life. The VAS scale 0 was the worst quality of life and scale 100 was the best quality of life. The changing of the quality of life was the changing of VAS of quality of life before and after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"15.8"},{"groupId":"OG001","value":"76.1","spread":"14.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":["soft tissue infection","nausea","leg pain"]}}}